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Abstract: Malignant gliomas are characterized by an intrinsic ability to invade diffusely 
throughout the normal brain tissue. This feature contributes mainly to the failure of existing 
therapies. Deregulation of small GTPases signaling, in particular Rac1 activity, plays a key 
role in the invasive phenotype of gliomas. Here we report the effect of ZINC69391, a specific 
Rac1 inhibitor developed by our group, on human glioma cell lines LN229 and U-87 MG. 
ZINC69391 is able to interfere with the interaction of Rac1 with Dock180, a relevant Rac1 
activator in glioma invasion, and to reduce Rac1-GTP levels. The kinase Pak1, a downstream 
effector of Dock180–Rac1 signaling, was also downregulated upon ZINC69391 treatment. 
ZINC69391 reduced cell proliferation, arrested cells in G1 phase, and triggered apoptosis in 
glioma cells. Importantly, ZINC69391 dramatically affected cell migration and invasion in vitro, 
interfering with actin cytoskeleton dynamics. We also evaluated the effect of analog 1A-116, 
a compound derived from ZINC69391 structure. 1A-116 showed an improved antiproliferative 
and antiinvasive activity on glioma cells. These findings encourage further preclinical testing 
in clinically relevant animal models.
Keywords: GTPases. invasion, Dock180, small molecule
Introduction
Gliomas are brain neoplasms with a glial cell origin and represent the most com-
mon primary tumors of the central nervous system in humans, with a patient mean 
survival of less than 1 year. The current treatment for gliomas includes the use of 
surgery, radio-, and chemotherapy.1 Despite their limited metastatic potential outside 
the central nervous system, gliomas are characterized by their high invasion potential 
throughout the brain. Migration and invasion of glioma cells is one of the most chal-
lenging processes that mainly contributes to the high frequency of tumor recurrence 
and tumor progression.2 Consequently, new therapeutic approaches are essential to 
improve treatment outcome.
A key group of molecules involved in glioma cell invasion are Rho GTPases. 
These proteins are molecular switches that cycle between two conformational states: 
an inactive GDP-bound form and an active GTP-bound form. This cycle is highly 
regulated by guanine nucleotide exchange factors (GEFs) that catalyze nucleotide 
exchange and mediate activation and GTPase-activating proteins that stimulate GTP 
hydrolysis and inactivate the GTPase.3,4 The active GTP-bound state binds preferen-
tially to downstream effector proteins, such as the p-21 activated kinase (Pak) family 
of proteins, and actively transduces signals.5
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
16
8.
96
.2
40
.2
 o
n 
08
-F
eb
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2022
cardama et al
H3C H3C
CH3 CH3
NH NH
NHNH NHNH
N
N
F F
F FF
BA
F
Figure 1 chemical structures of rac1 inhibitors.
Notes: (A) chemical structure of Zinc69391 (c14h15F3n5; molecular weight, 310.303). (B) chemical structure of 1a-116 analog (c16h16F3n3; molecular weight, 307.31).
Rac1 is one of the most studied members of the 
Rho GTPases family and controls fundamental cellular 
processes. Rac1 is a major regulator in actin cytoskeleton 
reorganization, affecting endocytosis and traff icking, 
cell cycle progression, and cell adhesion and migration. 
Accumulating evidence indicates that Rac1 is overex-
pressed and/or hyperactivated in a wide range of tumors.6 
In astrocytomas, Rac1 is overexpressed in high-grade 
tumors. Notably, the plasma membrane localization of Rac1 
observed in a subset of glioblastoma multiforme tumors, 
but not in low-grade astrocytomas or non-neoplastic brain, 
indicates that Rac1 is hyperactivated in glioblastomas.7 
Importantly, Rac1 was identified as a key molecule involved 
in the invasive behavior of gliomas. Many GEFs have been 
found to contribute to Rac1 activation and mediate glioma 
cell motility, such as Ect2, Vav3, Trio, and Dock180, 
among others.7,8
Due to their key role in many transforming events in 
different cancer types, Rho GTPases are therefore attractive 
and validated targets for anticancer therapies.9 Recently, we 
identified ZINC69391 as a small molecule that inhibited 
Rac1–GEF interaction and was able to affect cell prolifera-
tion, cell cycle progression, and migration of highly aggres-
sive breast cancer cell lines. Moreover, ZINC69391 inhibited 
lung metastasis in vivo. We further developed novel analogs 
using ZINC69391 as the parental compound and we showed 
that 1A-116 analog is a more potent Rac1 inhibitor in vitro 
and in vivo. Both ZINC69391 and 1A-116 had no effect on 
Cdc42 GTPase activation, a protein closely related to Rac1 
GTPase.10
Here, we report the biological activity of ZINC69391 on 
glioblastoma cells, showing a reduction of cancer cell growth 
associated with an elevated cell death, and a decrease in 
glioma cell migration and invasion in vitro. In line with our 
previous results, 1A-116 also showed to be a more potent 
agent on glioma cells.
Materials and methods
cell lines
Human glioblastoma multiforme cell lines LN229 (ATCC 
CRL-2611) and U-87 MG (ATCC HTB-14) were obtained 
from ATCC. Cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) or Minimum Essential Media 
(Thermo Fisher Scientific, Waltham, MA, USA), respectively, 
supplemented with 10% heat-inactivated fetal bovine serum, 
2 mM glutamine, and 80 µg/mL gentamicin at 37°C in 5% 
CO
2
 atmosphere. Cell cultures were routinely subcultured 
twice a week by trypsinization using standard procedures.
compounds
ZINC69391 (shown in Figure 1A) and 1A-116 (shown in 
Figure 1B) were synthesized as reported10 in Laboratorio de 
Síntesis Orgánica, Centro de Química, Instituto Nacional de 
Tecnología Industrial (INTI). Depending on the setting, con-
centrations between 10 and 100 µM were used as described 
in each experiment. Structures are shown in Figure 1.
cell proliferation assay
2.5×104 cells were plated in 96-well plates and then treated 
with different compounds for 72 hours. Cell growth was 
measured by colorimetric MTT assay (Sigma-Aldrich Co, 
St Louis, MO, USA).
The sequences of small interfering RNA (siRNA) for the 
sense and antisense strands were: for anti-Rac1 siRNA, sense 
5′- GUU CUU AAU UUG CUU UUC CTT -3′ and antisense 
3′-TTC AAG AAU UAA ACG AAA AGG-5′ were described 
elsewhere;11 and for control siRNA, sense 5′-CAG UCA 
GGA GGA UCC AAA GTT-3′ and antisense 3′-TTG UCA 
GUC CUC CUA GGU UUC-5′ as described elsewhere.12 
Synthetic oligonucleotides prepared by Thermo Fisher 
Scientific were annealed to form a short double-stranded 
RNA with a 3′-dithymidine overhang. On day 0, LN229 cells 
were plated on 60 mm dishes, grown until approximately 
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30%–50% confluency, and then transfected with Rac1 siRNA 
or control siRNA using Lipofectamine 2000 (Thermo Fisher 
Scientific), following manufacturer’s instructions. After 
4 days, cells were submitted to a second round of transfec-
tion under the same conditions. On day 7, 2.5×104 cells 
were plated in 96-well plates and then treated with different 
concentrations of 1A-116 for 72 hours. Cell growth was mea-
sured by colorimetric MTT assay. Results shown correspond 
to the average of three separate experiments.
Western blot
Cells were treated and lysed in lysis buffer. Cell lysates were 
clarified and quantified by Bradford. Equal amounts of total 
protein for each condition were boiled for 5 minutes in 4X 
sample buffer and resolved by 12% SDS-PAGE. Samples 
were then transferred to PVDF membranes (HybondP; 
Amersham Biosciences) and analyzed by Western blot-
ting using anti-Pak1 (Millipore) and anti–phosphor-Pak1 
(Millipore). Secondary antibody binding was detected by 
enhanced chemiluminescence.
Affinity precipitation of Rac1-Dock180
For Rac1-Dock180 precipitation assay, LN229 cells that 
express high endogenous levels of Dock180 were lysed 
in EDTA buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 
5 mM ethylenediaminetetraacetic acid, 0.5% NP-40, 5 mM 
β-glycerophosphate) supplemented with protease inhibitor 
cocktail. Lysates were cleared and 400 µg of total protein 
was used per condition. Glutathione Sepharose 4B beads (GE 
Healthcare) coupled with bacterially expressed glutathione 
S-transferase (GST)-Rac1 were preincubated with different 
concentrations of ZINC69391 for 30 or 15 minutes at 4°C 
and then added to each protein extract in the presence or 
absence of ZINC69391, using vehicle as control. The beads 
were washed twice with lysis buffer, resuspended in sample 
buffer, and boiled. The samples were analyzed by Western 
blot using mouse monoclonal anti-Dock180 antibody (Santa 
Cruz Biotechnology Inc., Dallas, TX, USA). The integrity 
of the purified fusion proteins was checked by SDS-PAGE 
and Coomassie blue staining prior to use in the assays 
described below.
rac1 pulldown assay
Tumor cells were plated at a density of 2.5×105 cells/well in 
six-well tissue plates, grown to 80% confluence, and starved 
for 48 hours. The cells were then treated for 1 hour with the 
compound and stimulated for 15 minutes with epidermal 
growth factor (EGF) 100 ng/mL (Thermo Fisher Scientific). 
Monolayers were washed with phosphate-buffered saline 
(PBS) and lysed in 150-GPLB buffer (20 mM Tris, pH 7.4, 
150 mM NaCl, 5 mM MgCl
2
, 0.5% NP-40, 10% glycerol, 
pH 7.4) supplemented with a protease inhibitor cocktail 
(Sigma-Aldrich Co). Lysates were clarified and the protein 
concentrations were normalized. An aliquot was removed for 
determination of total Rac1 and the rest was incubated with 
Glutathione Sepharose 4B Beads (GE Healthcare) coupled 
with bacterially expressed GST-Pak. Bound complexes were 
washed with lysis buffer, resuspended in protein sample buf-
fer, boiled, and loaded onto a 12% SDS-PAGE gel.  Proteins 
were transferred and blotted with mouse monoclonal anti-
body against Rac1 (Sigma-Aldrich Co).
cell cycle analysis
For cell cycle analysis by flow cytometry, cells were washed 
and incubated in serum-free DMEM for synchronization for 
24 hours. Cells were then treated for 48 hours with differ-
ent concentrations of ZINC69391 in DMEM supplemented 
with 10% fetal bovine serum and collected by trypsinization. 
Cells were fixed in 70% methanol in PBS and stained with 
propidium bromide (1 mg/mL) (Thermo Fisher Scientific). 
Cell cycle progression was analyzed in a BD FACSCalibur™ 
(BD Biosciences, San Jose, CA, USA) flow cytometer. Before 
recording 10,000 events, the verification of the doublet dis-
crimination function of the flow cytometer was performed 
with a DNA QC Particles kit (BD Biosciences).
actin staining
Cells grown in glass cover slips were incubated overnight 
(16 hours) in serum-free DMEM, treated for 1 hour with 
ZINC69391, and then stimulated with EGF (100 ng/mL) 
(Thermo Fisher Scientific) for 15 minutes. Cells were fixed 
in 4% formaldehyde in PBS and stained with AlexaFluor555 
conjugated phalloidin (Molecular Probes; Thermo Fisher 
Scientific) following the manufacturer’s instructions. Images 
were recorded in an inverted fluorescence microscope (Nikon 
Eclipse T2000; Nikon Corporation, Tokyo, Japan).
Transwell migration assay
Cells were starved overnight in DMEM media, and 1×105 
cells were preincubated with or without ZINC69391 for 
30 minutes and then added to the top chambers of 24-well 
transwell plates (Nunc; 8 µm pore size). Media with 10% 
FCS was added to the bottom chambers. After overnight 
incubation, top (nonmigrating) cells were removed and 
bottom (migrating) cells were fixed and stained with crys-
tal violet. The number of migrating cells in five fields was 
counted. The experiments were repeated a minimum of 
three times.
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Transwell invasion assay
Transwell chambers were coated with 100 µL of a 0.8 mg/mL 
Matrigel suspension and dried at room temperature. Using 
1.5×105 cells and 48 hours’ incubation, the assay was con-
ducted as for the migration assay.
apoptosis
For annexin V early apoptosis determination, Annexin 
V- Alexa488/Cell dead apoptosis kit (Molecular Probes; 
Thermo Fisher Scientific) was used. Cells growing in glass 
cover slips were treated for 6 hours with 10 µM and 50 µM 
ZINC69391 and then stained according to manufacturer’s 
protocol. For terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) assay, DeadEnd Fluorometric TUNEL 
System (Promega Corporation, Fitchburg, WI, USA) was 
used. Apoptosis was determined using manufacturer’s protocol 
using the same experimental setting described for Annexin V 
Apoptosis determination.
Results
Zinc69391 inhibited rac1 interaction 
with Dock180, a relevant geF  
in glioma biology
ZINC69391 was developed as a Rac1 activation inhibitor, 
interfering with Rac1–GEF interaction by masking Trp56 
residue on Rac1 surface. Dock180 belongs to the atypical 
family of GEFs and has been shown to have an important role 
on glioma cell migration.8 The Dock family of GEFs show 
little homology to the classical Dbl family members, but it has 
been shown that Trp56 residue on Rac1 is a key residue for 
specific Dock180–Rac1 recognition.13 Thus, we determined 
the effect of ZINC69391 treatment on Rac1–Dock180 interac-
tion. Because it was reported that LN229 expresses high levels 
of Dock180,8 this cell line was used to assess Rac1–Dock180 
interaction. LN229 lysates were incubated with GST-Rac1 
coupled with glutathione agarose beads in the presence or 
absence of ZINC69391. As seen in Figure 2A, ZINC69391 
was able to block Rac1–Dock180 interaction in vitro starting 
at 50 µM, showing that ZINC69391 is also able to block Rac1 
interaction with the atypical family of GEFs.
Zinc69391 inhibited egF dependent 
rac1 activation and downstream 
phosphorylation of Pak1 in a 
concentration-dependent manner
We next tested the ability of ZINC69391 to reduce Rac1 
activation on LN229 cells. LN229 were serum-starved 
overnight, treated for 1 hour, and then stimulated with EGF. 
The cell lysates were subjected to pulldown assays and Rac1-
GTP was determined using a Rac1 monoclonal antibody. 
Figure 2B shows that treatment with ZINC69391, prior to 
EGF stimuli, dramatically impaired Rac1 pathway activation 
by this growth factor in a concentration-dependent manner; 
whereas total Rac1 levels remained unchanged. Remarkably, 
high concentrations of ZINC69391 reduced Rac1 activation 
below nonstimulated basal levels.
In addition, we tested the effect of ZINC69391 on a 
relevant Rac1 effector Pak1 that has been shown to play an 
important role in proliferation, survival, and invasiveness of 
cancer cells.14 More critically, Pak1 phosphorylation in the 
cytoplasm of cancer cells correlates with shorter survival of 
glioma patients.15 ZINC69391 reduced Pak1 phosphorylation 
in a concentration-dependent manner using the same experi-
mental scenario as described above. ZINC69391 showed 
Pak1 phosphorylation inhibition at 10 µM in the presence 
of EGF, but higher concentrations reduced phospho-Pak 
levels leading to activation levels similar to those found 
in the unstimulated condition (Figure 2C). This molecular 
evidence in addition to inhibition of Rac1 activation and 
of Rac1–Dock180 interaction shows that ZINC69391 is an 
effective Rac1-axis inhibitor.
Zinc69391 triggered cell cycle  
arrest and reduced cell proliferation  
of human glioma cells
We then analyzed the effect of ZINC69391 on cellular 
proliferation of glioma cells. After 72 hours’ treat-
ment, cell viability was measured using the MTT assay. 
Treatment of U-87 MG and LN229 cells with ZINC69391 
reduced cell proliferation in a concentration-dependent 
manner (Figure 3A). To further delineate the mechanism 
of cell-proliferation inhibition, we analyzed the cell 
cycle distribution after ZINC69391 treatment of LN229 
cells. Of interest, Rac1 has been shown to control signal 
transduction pathways that are essential for cell growth 
by modulating cell cycle progression through G1 phase 
through cyclin D1 expression.16 As expected, ZINC69391 
treatment resulted in a significant increased percentage 
of cells in the sub-G0/G1 phase (Figure 3B) in a concen-
tration dependent manner.
rac1 inhibition by Zinc69391  
induced apoptosis on glioma cells
Since sub-G0 population is often used to estimate 
 apoptosis17 and we determined that ZINC69391  treatment 
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ZINC69391 (µM)
ZINC69391 (µM) − − 10 25 50 100
                  EGF − + + + + +
ZINC69391(µM) − − 5 10 25 50
                  EGF − + + + + +
0
1 0.21 0.40 0.22
A
B
C
0.95 1 0.81 0.85 0.86 0.58
0.44 1 1.03 0.76 0.43 0.41
Pak
pPak
Rac1-GTP
Total Rac1
50 100 200
Dock180
α-Tubulin
Figure 2 Zinc69391 inhibited rac1 activation on ln229 glioma cells.
Notes: (A) Blockade of Rac1–Dock180 interaction. Dock180 was affinity-precipitated with bacterially expressed Rac1 immobilized in glutathione agarose beads in 
the presence of varying concentrations of Zinc69391. Western blot analysis was carried out with anti-Dock180 antibody. The experiment was repeated three times. 
Densitometric values are shown below (arbitrary units). (B) concentration-dependent rac1 inhibition by Zinc69391 in glioma cells. serum-starved ln229 cells were treated 
for 1 hour with different Zinc69391 concentrations and stimulated with epidermal growth factor (egF) (100 ng/ml) for 15 minutes. Densitometric values are shown below 
(arbitrary units). (C) concentration-dependent inhibition of Pak1 phosphorylation using the same experimental procedure as before. Densitometric values are shown below 
(arbitrary units).
results in an increase in this population, we further 
evaluated the proapoptotic effect of this compound. Rac1 
inhibition has long been reported to trigger apoptosis 
in many different cancer types. Particularly in glioma 
cells, Rac1 suppression induces apoptosis in cell lines 
and short-term primary cultures of grade III and grade 
IV gliomas.18
To evaluate whether ZINC69391 induces apoptosis, we 
used two different techniques. First, we analyzed apoptosis 
using annexin V, which measures the loss of the  phospholipid 
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Figure 3 Zinc69391 affected cell proliferation and cell cycle progression of glioma cells.
Notes: (A) Zinc69391 inhibited cell proliferation. ln229 and U-87 Mg cells were treated for 72 hours with different concentrations of Zinc69391. cell viability was 
measured using MTT assay. (B) Zinc69391 arrested cell cycle progression in g1 phase. ln229 cells were synchronized and treated for 48 hours with Zinc69391 with different 
concentrations. Cells were fixed, stained with propidium iodide, and analyzed by flow cytometry to estimate the percentage of cells in sub-G0 phase, G1 phase, S phase, and G2/M 
phase. Bars, standard error of the mean. *P,0.05, **P,0.01 determined by analysis of variance contrasted. Dunnett’s multiple comparison test versus control in each phase.
membrane asymmetry of the cell as an early indicator of 
apoptosis. In this case, cells were treated for 6 hours with 
different concentrations of ZINC69391 and then stained with 
Annexin V-Alexa488 following manufacturer’s protocol. As 
seen in Figure 4A, ZINC69391 was able to trigger apoptosis 
starting at a concentration of 10 µM. To further confirm the 
induction of programmed cell death by ZINC69391, we 
performed a TUNEL assay, which detects DNA breakage that 
occurs during late stage of apoptosis. Under the same experi-
mental conditions as before, ZINC69391 presented a signifi-
cant proapoptotic effect starting at 10 µM (Figure 4B and C). 
In summary, we demonstrated by two different methodologies 
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that ZINC69391 presents a proapoptotic activity by inhibition 
Rac1 activation.
Zinc69391 dramatically affected cell 
migration and invasion of aggressive 
glioma cells
Rac1 plays a critical role in the invasive behavior of 
gliomas. This GTPase regulates lamellipodia formation, 
cell migration, and invasion in glioma cells.19 Thus, we 
examined the effect of ZINC69391 on cell migration of 
LN229 cells in a transwell assay. Treatment of cells with 
ZINC69391 10 µM for 24 hours significantly reduced cancer 
cell migration showing a concentration-dependent inhibi-
tion (Figure 5A).
Since it is established that mechanisms that regulate 
cell migration are fundamental to the invasive phe-
notype of gliomas,2 we expected ZINC69391 to be able 
to reduce cell invasion also. Therefore, we determined the 
effect of ZINC69391 treatment on the invasive proper-
ties of LN229 using a transwell Matrigel invasion assay. 
Interestingly, ZINC69391 significantly reduced cell inva-
sion in a concentration-dependent manner, starting at 
10 µM (Figure 5B).
Rho GTPases are key regulators of cytoskeleton reor-
ganization, the mechanism underlying cell motility and 
invasion processes.20 We therefore investigated the effect of 
ZINC69391 on actin reorganization using phalloidin staining. 
Since phalloidin stains polymerized actin, we show that 
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Figure 4 Zinc69391 triggered apoptosis on malignant glioma cells.
Notes: (A) apoptosis of ln229 cells after 10 µM and 50 µM treatment for 6 hours using annexin V staining. representative micrographs taken at 200×. (B) late apoptosis 
was evaluated at 10 µM and 50 µM for 6 hours using TUnel assay. representative micrographs taken at 100×. (C) Quantification of apoptotic cells per field using TUNEL 
assay. Bars, standard error of the mean, *P,0.05, **P,0.01 determined by analysis of variance cont. Dunnett’s multiple comparison test versus control.
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Figure 5 Zinc69391 inhibited glioma cell migration and invasion modulating actin cytoskeleton reorganization.
Notes: (A) ln229 cells were seeded in uncoated transwell chambers with or without Zinc69391, incubated for 18 hours, and quantified. Bars, standard error of the mean. 
*P,0.05; ***P,0.001 determined by analysis of variance cont. Dunnett’s multiple comparison test. (B) ln229 cells were seeded in Matrigel-coated transwell chambers 
with or without Zinc69391, incubated for 48 hours, and quantified. Bars, standard error of the mean. *P,0.05; **P,0.01; ***P,0.001 determined by analysis of variance 
cont. Dunnett’s multiple comparison test. (C) representative micrographs taken at 1,000× showing inhibition of epidermal growth factor (egF)-induced actin reorganization 
by Zinc69391 in ln229 cells. cells were grown on cover slips, serum-starved for 16 hours (untreated panel), and treated for 1 hour with Zinc69391. after 15 minutes 
stimulation with EGF (100 ng/mL) (EGF control), cells were fixed and actin filaments were visualized with AlexaFluor555-phalloidin.
ZINC69391 is able to disrupt actin polymerization induced by 
EGF stimulation. Treatment of cells with 10 µM Zinc69391 
markedly affected the dynamic reorganization of actin, while 
with a concentration of 50 µM Zinc69391 the effect is much 
more evident. ZINC69391 was not able to block completely 
actin poly merization, but presented a profound effect on actin 
filaments in the cytoplasm (Figure 5C).
Zinc69391-derived 1a-116 analog 
presented enhanced rac1-mediated 
antiproliferative and antiinvasive activity
We have previously reported the development of a novel 
analog that showed to be more potent than the parental 
ZINC69391 compound in aggressive breast cancer cell mod-
els in vitro and in vivo.10 To evaluate the effect of 1A-116 
on cell proliferation of LN229 and U-87 MG cells, we mea-
sured cell viability by the MTT metabolic assay. 1A-116 
inhibited cell proliferation in a concentration-dependent 
manner, as shown in Figure 6A.
To further investigate whether these compounds present 
a Rac1-mediated antiproliferative effect, we evaluated the 
effect of 1A-116 on LN229 cells where Rac1 was depleted 
using siRNA. As shown in Figure 6B, silencing of Rac1 
significantly attenuated the inhibitory effects of 1A-116 on 
cell proliferation compared to control siRNA transfected 
cells. This result confirms that 1A-116 affects Rac1 signaling 
pathway, resulting in a reduction of cell proliferation.
We tested 1A-116 effect on in vitro invasion of LN229 
cells by carrying out a transwell Matrigel invasion assay 
as previously described. Treatment with 50 µM 1A-116 
resulted in a significant reduction of cell invasion, as shown 
in Figure 6C. Remarkably, 1A-116 analog demonstrated 
an enhanced antiinvasive activity compared to the parental 
compound ZINC69391.
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Figure 6 1a-116 analog is a more potent rac1 inhibitor.
Notes: (A) ln229 and U-87 Mg cells were treated for 72 hours with different concentrations of Zinc69391 and 1a-116. cell viability was measured using MTT assay. 
(B) ln229 were transiently transfected with rac1 small interfering (si)rna or control sirna. cells were treated for 72 hours with different concentrations of 1a-116 analog 
and cell viability was measured using MTT assay. (C) ln229 cells were seeded in Matrigel-coated transwell chambers with or without Zinc69391, incubated for 48 hours, 
and quantified. **P,0.01, ***P,0.001. Determined by analysis of variance contrasted with Dunnett’s multiple comparison test.
Discussion
Several studies have showed that deregulated activities 
of Rho GTPases, such as Rac1, in malignant gliomas are 
responsible for the highly invasive and infiltrative  phenotype 
of these brain cancers. Although it has recently been 
described a gain-of-function mutation in rac1 gene in sun-
exposed melanomas,21,22 to date, these mutations have not 
been found in other cancer types, including glioblastomas. 
Despite the fact that activating mutations of rac1 were not 
found, Rac1 protein levels correlate with tumor grade and 
poor survival in glioblastoma patients.7 In addition, immu-
nohistochemistry analyses present a prominent plasma 
membrane staining of Rac1 in human high-grade glioblas-
toma specimens, indicating a high activation level of these 
proteins. This hyperactivation can be explained at least in part 
by the overexpression of different GEFs, such as Trio, Ect2, 
Vav3, and Dock180, among others.7 Importantly, studies have 
shown that Rac1 contributes to chemotherapy resistance23 and 
promotes radiation-therapy-induced glioma cell invasion.24 
Rac1 is also critically involved in the enrichment of the 
glioma stem-like cell population and tumorigenicity in 
human glioma. Moreover, Rac1 inhibition on glioma stem-
like cells enhanced radiation sensitivity.25 Rac1 has also been 
involved in angiogenesis in different tumoral settings, such 
as neuroblastoma26 and breast cancer.27 Inhibition of Rac1 
using siRNA reduces vascular endothelial VEGF-mediated 
tubule formation, migration, and invasion in vitro, and these 
findings also are seen in vivo. In line with all this, targeting 
Rac1 activation may be a useful therapeutic strategy for 
glioblastoma treatment.
In our previous study, we reported the activity of 
ZINC69391, a novel Rac1 inhibitor with biological activity 
on aggressive breast cancer cells. ZINC69391 affected breast 
cancer cell proliferation and migration in vitro and showed a 
significant reduction by approximately 60% of total metastatic 
lung colony formation in a syngeneic animal model.10
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Initially, we searched for molecules capable of binding 
Rac1 protein surface containing the critical Trp56 residue. 
Since Trp56 is a key residue in Rac1 recognition, we expected 
ZINC69391 may interfere with Rac1 activation by GEFs 
sharing the same activation mechanism. Two structurally 
unrelated families of GEFs have been described so far: the 
classical Dbl and the atypical Dock180-related families. The 
mechanism involving Trp56 by which many Dbl-GEFs bind 
and activate Rac1 has been known for more than a decade.28,29 
More recently, it has been described that Dock180 also shares 
the same residue as a determinant for specific recognition 
for Rac1.13 In support of this, we have already shown that 
ZINC69391 was able to interfere with Rac1–Tiam1 (a Dbl-
family GEF) recognition and now our results demonstrate that 
ZINC69391 also blocks Rac1–Dock180 interaction. Dock180 
has been characterized to contribute to the enhancement 
of glioma cell migration and invasion via Rac1 activation. 
Immunohistochemical analyses on primary human malig-
nant glioma specimens showed that Dock180 is expressed in 
infiltrating tumor cells within the border and invasive areas 
compared to the central core of the tumor, independent of 
tumor grade. On the other hand, Dock180 was not detected 
in normal brain tissue.8 This may have important therapeutic 
implications, since all malignant gliomas are characterized to 
invade diffusely, including low-grade astrocytomas.1 Dock180 
expression may be involved in the early onset of the disease, 
driving the diffusely infiltrative nature of malignant gliomas. 
Moreover, Dock180 was found to be involved in the signaling 
pathways that mediate PDGFRα- and EGFRvIII-driven tum-
origenesis and invasion in glioma via Rac1 activation.30,31
In line with the evidence indicating that ZINC69391 
blocks Rac1–Dock180 interaction, ZINC69391 effectively 
reduced endogenous Rac1 activation levels, presenting a 
concentration-dependent inhibition in response to EGF 
stimulation. Cells treated with ZINC69391 and stimulated 
with EGF showed Rac1-GTP levels that remained equal or 
were lower than the unstimulated condition. We also examined 
the effect of ZINC69391 treatment on Pak1 phosphorylation. 
Pak1 is a serine/threonine protein kinase that mediates 
cytoskeletal remodeling and cell motility through actin and 
microtubules.32 Initially, Pak1 was determined to be activated 
by Rac1 and Cdc42, and to be an important mediator of 
these GTPases in the brain.33 Pak1 is widely expressed in a 
variety of normal tissues, and its expression is significantly 
increased in different cancers.34 In malignant glioblastoma, 
immunohistochemical analysis showed that phosphorylated 
Pak1 levels in the cytoplasm of glioma specimens correlated 
with shorter survival time in patients.15 Our results present 
that treatment of LN229 cells with ZINC69391 reduced Pak1 
phosphorylation in a concentration-dependent manner upon 
EGF stimulation. Phosphorylated Pak1 levels were found to 
be lower than the unstimulated condition, when cells were 
treated with 25 µM and 50 µM ZINC69391 in the presence 
of EGF. These results demonstrate that ZINC69391 inhibits 
Dock180/Rac1/Pak1 signaling pathway on glioma cells in 
vitro.
In agreement with observations that used expression of 
dominant-negative Rac1 to inhibit proliferation and survival 
of glioma cell lines,18,19 ZINC69391 treatment showed anti-
proliferative activity in LN229 and U-87 MG cell lines. This 
inhibition was associated with a cell cycle arrest in G1 phase. We 
also showed an increase in sub-G0 cell population, suggesting 
apoptosis induction. Then, we evaluated the proapoptotic activity 
of ZINC69391. Annexin V and TUNEL studies established that 
ZINC69391 induces apoptosis on glioma cell lines at 10 µM and 
50 µM, having no effect on cell detachment (data not shown). 
These findings are in agreement with observations that used 
recombinant adenoviruses expressing dominant-negative Rac1 
on glioma cell lines and glioblastoma primary cultures to sup-
press Rac1 activity.18 Senger et al showed that Rac1 inhibition 
induces apoptosis in glioma cells but not in normal human 
astrocytes. These data provide a solid rationale for Rac1 target-
ing in malignant gliomas, with a selective effect on the tumor. 
The mechanism by which glioma cells undergo apoptosis upon 
ZINC69391 treatment remains unknown. Of interest, at least 
two signaling pathways have been described to contribute to 
Rac1-mediated survival on glioma cells: JNK and MAPK. The 
dominant pathway is proposed to be Pak1-JNK pathway.18 Here 
we show a direct effect on Pak1 phosphorylation, but further 
experiments are necessary to address the effect of ZINC69391 
on JNK activity and to determine the pathways and the modu-
lation of different molecules involved in the apoptotic process, 
such as caspase 3.
As previously mentioned, diffuse cell migration and inva-
sion are key properties of malignant gliomas. This invasive 
behavior has major therapeutic implications, since it is the 
major driver of glioma recurrence and therapeutic failure.1 
Surgery is unable to cure patients even when the lesions arise in 
areas in which wide surgical resection is possible, since glioma 
cells infiltrate throughout the brain. Of interest, several studies 
have reported that ionizing radiation enhances the invasion of 
glioma tumor cells.35,36 Cancer invasion and drug resistance 
are thought to be interconnected with the processes promoting 
tumor progression and therapeutic failure.37
Rac1 and Rho GTPases in general have long been known 
as modulators of cell motility in normal tissues and disease 
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tissues.20 Particularly in glioblastomas, the spatial regulation of 
Rho GTPases activity has been studied in detail using biosen-
sors in vivo and in 3D substrates. In both models, glioblastoma 
cells leading the invasion had higher Rac1 and Cdc42 activities 
and guided the trailing glioma cells with lower Rac1 and Cdc42 
activities.38 This differential activation pattern indicates het-
erogenic invasion potential in different cell populations within 
the tumor. Importantly, Rac1 GEFs such as Ect2, Vav3, and 
Trio have been implicated in glioblastoma cell invasion39 and 
Dock180 has been implicated in EGFRvIII-driven invasion.30 
This shows that Rac1 axis is important for glioma motility. In 
agreement with observations that used expression of dominant-
negative Rac1 and siRNA Rac1 to interfere with glioma cell 
invasion, our data indicate that ZINC69391 modulates actin 
cytoskeleton dynamics, inhibiting cell migration and having a 
significant impact on cell invasion in vitro. Depleting Rac1 on 
glioma cells using these molecular biology strategies achieved 
approximately 80% inhibition of cell invasion.19 Our data 
indicate that modulation of Rac1 by ZINC69391 resulted in 
approximately 50%, 60%, and 85% cell invasion with 10 µM, 
50 µM, and 100 µM treatment, respectively, leading to similar 
results compared to dominant-negative experiments using a 
pharmacological agent.
Our data also show the increased potency of 1A-116 
analog compared to parental ZINC69391 compound. This 
analog was rationally designed using ZINC69391 as a lead 
structure and was selected from a group of analogs because 
better docking scores correlated with an improved in vitro 
and in vivo potency on an aggressive breast cancer model. 
Importantly ZINC69391 and analog 1A-116 showed to be 
more potent inhibitors than the described Rac1 inhibitor 
NSC23766 on cancer cells in vitro (IC
50
 [half maximal 
inhibitory concentration] values: NSC23766: 140 µM, 
ZINC69391: 61 µM, 1A-116: 4 µM).10 Interestingly, 1A-116 
analog presented also an improved antiproliferative activity 
compared to the parental analog on glioma cells and this 
antiproliferative activity showed to be Rac1 dependent using 
siRNA probes. These results are in line with previous work, 
where the overexpression of a constitutively active form of 
Rac1 (G12V) attenuated the inhibitory effect of 1A-116 
analog on breast cancer cells. Together, this demonstrates 
that the effect of this molecule is mediated by Rac1. We 
also show that 1A-116 analog is a more potent antiinvasive 
compound using Matrigel-coated transwells, a key feature 
for an anticancer agent for glioma treatment.
Because one common obstacle in the treatment of glio-
blastoma patients is chemoresistance, the need to combine 
different agents to overcome resistance mechanisms is 
becoming more evident. In line with this idea, combination 
schemes with our Rac1 inhibitors and chemotherapeutic 
drugs used for glioblastoma treatment such as temozolomide 
may potentially show a therapeutic benefit. Currently we are 
evaluating these combination schemes. Sooman et al showed 
by bioinformatics and in vitro studies that camptothecin, 
a topoisomerase I inhibitor, and imatinib, a tyrosine kinase 
inhibitor, combined with a Rac1 inhibitor had a synergistic 
effect on human glioblastoma cell lines.40 Karpel-Massler 
et al also reported that the combination of erlotinib, an 
EGFR inhibitor, and a Rac1 inhibitor presented a synergistic 
effect on established glioma cell lines and primary glio-
blastoma cells.41 Collectively, several studies indicate that 
targeting Rac1 may be associated with a therapeutic benefit, 
although Rac1 is also involved in physiological events such 
as vessel permeability indicating that targeting Rac1 could 
lead to leaky vessels. A detailed toxicological study must be 
conducted to evaluate which adverse effects are relevant in 
a therapeutic scheme with a Rac1 pharmacological inhibitor 
in vivo. These experiments are being conducted.
Taken together, this study provides evidence that 
Dock180/Rac1/Pak1 signaling pathway is downregulated by 
ZINC69391 compound leading to inhibition of cell prolifera-
tion and cell invasion on glioblastoma cell lines. Treatment 
with ZINC69391 arrested glioma cells in G1 phase, triggered 
apoptosis, and modulated actin cytoskeleton dynamics, 
resulting in inhibition of cancer cell motility. We also show 
that 1A-116 analog inhibits in vitro proliferation and invasion 
more efficiently. Our results encourage further preclinical 
testing in clinically relevant animal models.
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